Namodenoson in 20-Patient Phase IIa Pancreatic Trial Meets Safety Endpoint
Can-Fite’s Phase IIa open-label study of namodenoson in 20 advanced PDAC patients who had progressed after prior therapies met its primary safety endpoint with no new safety signals identified. One third of patients remain alive at data cut-off and survival outcomes are expected to mature before upcoming scientific meetings.
1. Study Design and Patient Cohort
The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following one or more prior systemic therapies.
2. Safety Results
Namodenoson’s safety profile met the primary endpoint with no new safety signals identified and was consistent with its known clinical tolerability in other oncological indications.
3. Survival Follow-Up and Next Steps
At data cut-off, one third of patients remained alive and survival outcomes including overall and progression-free survival are expected to mature, guiding further clinical evaluation and potential presentations at upcoming scientific meetings.